Decision

September 2021 Promotion of finasteride by Careforsons Limited t/a Sons

Published 14 December 2021

A member of the public contacted MHRA to raise concerns about the information provided for finasteride on the Sons website. The complainant did not consider that the mental-health side-effects and emotional wellbeing were sufficiently or appropriately discussed on the webpages where this prescription-only medicine was highlighted.

MHRA contacted Careforsons Limited regarding the concerns and asked them to review their website to ensure readers are given a balanced overview of the potential risks and benefits of using this medicine and to avoid absolute statements of safety. You can see details of MHRA guidance for providers that offer medicinal treatment services in Appendix 6 of the MHRA Blue Guide.